Zevra Delivers Strong Q4 2025 Financial Results and Sets Stage for Growth in 2026
On March 9th, Zevra's management team, including President and CEO Neil McFarlane, Chief Commercial Officer Josh Shafer, and Chief Medical Officer Adrian Quartel, hosted a conference call to discuss the company's Q4 and full-year 2025 financial results. The call provided valuable insights into Zevra's progress and future prospects.
Notably, Zevra reported net revenue of $106.5 million for 2025, driven primarily by the commercial stage performance of MIPLYFFA, which generated $87.4 million in revenue. In Q4, the company recorded $34.1 million in total net revenue, with MIPLYFFA sales contributing $26.4 million.
MIPLYFFA, Zevra's foundational treatment for Niemann-Pick disease type C (NPC), continued to demonstrate strong commercial performance in Q4, with 24 prescription enrollment forms received, bringing the total since launch to 161 enrollments and 52 enrollment forms in the first full year of commercialization. This trend indicates increasing penetration and access to therapy for patients.
The growth of MIPLYFFA is being driven by previously diagnosed patients and increasingly by newly diagnosed patients, which reinforces Zevra's confidence in the estimated U.S. prevalence of approximately 900 affected individuals, with 300-350 currently diagnosed. This confidence is further bolstered by the success of initiatives aimed at identifying newly diagnosed patients.
Zevra's management emphasized that MIPLYFFA has exclusivity in the U.S. through 2031 under Orphan Drug Designation and that they are diligently pursuing a patent term extension, which would represent positive upside to their existing runway. The company is also expanding access to MIPLYFFA globally through its expanded access program (EAP), with 113 patients enrolled at the end of 2025.
As Zevra looks ahead to 2026, management is optimistic about the prospects for growth, driven by multiple initiatives and a strong commercial foundation. The company's focus on patient centricity, integrity, accountability, innovation, and courage guides its strategic plan and underpins its commitment to delivering life-changing therapies to people living with rare diseases.
